News

The financing was led by new investor Arix Bioscience plc, and included Pivotal bioVenture Partners, Advent Life Sciences, Domain Associates and Bay City Capital. All of Iterum’s current

Zykadia, which is to be subjected orally, is a selective inhibitor of the ALK gene. Capable of combining with other genes to form an abnormal fusion protein, the

Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor. This BLA includes data from pivotal studies in patients with episodic and chronic

The FDA had previously informed the Company that it could initiate the Phase 2a clinical trial; however, subsequent to its initiation, but prior to dosing subjects, the FDA

The company has reported positive topline phase 3 results for the HELP study, which assessed the efficacy and safety of subcutaneously administered lanadeluma against placebo over 26 weeks

These data include results from pooled analyses of three Phase 1 expansion cohorts and from a Phase 1b/2 study, FORWARD II, evaluating mirvetuximab soravtansine in combination with Avastin

The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with malignant

The priority review has been specifically designated for treatment of FL patients whose disease had relapsed or is in the refractory stage and had also received at least

The target indication for CIRARA is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share